Tafoxiparin is protected by several patent families

Dilafor´s drug product candidate tafoxiparin, is protected by several patent families with basic patent expiries in 2023-2034. Substance patent protection for tafoxiparin has been granted worldwide, with just a few countries remaining to be granted due to slower patent examination procedures. Further patent applications are also on file, covering additional aspects of Dilafor´s development programme.

“I am delighted that my 40 years’ preclinical and clinical research have reached this significant milestone. There is a great medical need for new treatments to address protracted labor and I hope that tafoxiparin will make a difference for all these pregnant women.”

Professor Gunvor Ekman Ordeberg, Founder and CMO at start of phase IIb